MTHFR polymorphisms' influence on outcome and toxicity in acute lymphoblastic leukemia patients
- Resource Type
- Authors
- Giovanni Reddiconto; Alessia Fiorini; Patrizia Chiusolo; Giuseppe La Torre; Giuliana Farina; Luca Laurenti; Mariangela Palladino; Simona Sica; Alice Mannocci; Federica Sorà; Giuseppe Leone; Luana Fianchi
- Source
- Leukemia research. 31(12)
- Subject
- Oncology
Adult
Male
Cancer Research
medicine.medical_specialty
Adolescent
Drug-Related Side Effects and Adverse Reactions
Genotype
Lymphoblastic Leukemia
Relapse free survival
Recurrence
Internal medicine
medicine
Humans
Point Mutation
Child
Survival rate
Childhood Acute Lymphoblastic Leukemia
Methylenetetrahydrofolate Reductase (NADPH2)
Aged
Polymorphism, Genetic
biology
business.industry
Hematology
Middle Aged
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Survival Rate
Methotrexate
Treatment Outcome
Methylenetetrahydrofolate reductase
Toxicity
Immunology
biology.protein
Female
business
medicine.drug
- Language
- ISSN
- 0145-2126
Recently the influence of polymorphisms of different genes involved in metabolism of chemoterapic agents have been studied especially in childhood acute lymphoblastic leukemia (ALL). We evaluated the influence of C677T and A1298C methylenetetrahydrofolate reductase (MTHFR) polymorphisms on time to relapse and survival and on methotrexate (MTX) toxicity in 82 ALL adult patients. Relapse free survival and event free survival between homozygous wild-type and variant patients in both polymorphisms were not significantly different. However, we observed an association between 677TT variant and survival in a subset of ALL patients homogenously treated with MTX-based maintenance (p=0.02). In the same subgroup we confirmed the role of 677TT variant on toxicity during MTX treatment (p=0.003).